+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID06230055

Study of Intrathecal Chemotherapy with Ommaya Reservoir Plus Systemic Chemotherapy Compared to Systemic Chemotherapy Alone in Adults with HER2-Negative Breast Cancer and Leptomeningeal Metastasis

Led by Fudan University · Updated on 2025-11-25

37

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the clinical effectiveness and quality of life impact of intrathecal chemotherapy delivered through an Ommaya reservoir combined with systemic chemotherapy versus systemic chemotherapy alone in patients with HER2-negative breast cancer who have leptomeningeal metastasis. This prospective, multicenter, randomized controlled, open-label clinical study aims to compare these treatment approaches in this patient group. Participants are assigned to one of two groups one receiving intrathecal chemotherapy via an Ommaya reservoir along with systemic chemotherapy, and the other receiving systemic chemotherapy alone. The intrathecal chemotherapy drugs include methotrexate, thiotepa, cytarabine, cytarabine liposome, pemetrexed, or DS8201, with dosing cycles every 1 to 3 weeks. Systemic chemotherapy options include capecitabine, gemcitabine, vinorelbine, docetaxel, nab-paclitaxel, iribrin, DS8201, sacituzumab govitecan, or SKB264, with varied dosing schedules. During the study, participants will be regularly monitored through clinical assessments and laboratory tests to evaluate neural progression-free survival, which is measured six months after the last patient enrollment. Researchers will also assess quality of life and follow participants over time to monitor safety and treatment outcomes. The study is led by Fudan University and includes adults aged 18 years and older with confirmed HER2-negative metastatic breast cancer and leptomeningeal metastasis.

CONDITIONS

Brief Title

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

Research Team

J

Jian Zhang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here